1	Per- and polyfluoroalkyl substances concentrations are associated with an unfavorable cardio-metabolic						
2	risk profile: findings from two population-based cohort studies						
3							
4	Authors: Tariq O. Faquih ^{1*} , Elvire N. Landstra ^{2*} , Astrid van Hylckama Vlieg ¹ , N.Ahmad Aziz ^{2,3} , Ruifang Li-						
5	Gao ^{1,4} , Renée de Mutsert ¹ , Frits R. Rosendaal ¹ , Raymond Noordam ⁵ , Diana van Heemst ⁵ , Dennis O. Mook-						
6	Kanamori ^{1, 6} , Ko Willems van Dijk ^{7,8,9} , Monique M.B. Breteler ^{2,10}						
7	¹ Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands						
8	² Population Health Sciences, German Centre for Neurodegenerative Diseases (DZNE), Bonn, Germany						
9	³ Department of Neurology, Faculty of Medicine, University of Bonn, Bonn, Germany						
10	⁴ Metabolon, Inc. Morrisville, North Carolina, United State of America						
11	⁵ Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center,						
12	Leiden, The Netherlands						
13	⁶ Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands						
14	⁷ Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands						
15	⁸ Department of Internal Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The						
16	Netherlands						
17	⁹ Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The						
18	Netherlands						
19	¹⁰ Institute for Medical Biometry, Informatics and Epidemiology (IMBIE), Faculty of Medicine, University of						
20	Bonn, Germany						
21							
22	*Authors contributed equally to this project						
23							
24	Abstract word count: 244						
25	Main manuscript word count: 3735						
26	Number of tables: 2						
27	Number of figures: 3						
28	Number of supplementary tables: 2						
29	Number of supplementary figures: 1						
30							
31	Keywords: PFAS exposure, general population, cohort study, metabolomics, lipoproteins, cardiovascular						
32	disease risk, meta-analysis						
33							
34	Corresponding author:						
35	Monique M.B. Breteler						
36	Monique.Breteler@dzne.de						
37	Venusberg-Campus 1, Building 99						
38	53127 Bonn, Germany						
39							

40 Acknowledgements

- 41 We would like to thank all participants and the study personnel of the Rhineland Study. The authors of the NEO
- 42 study thank all participants, all participating general practitioners for inviting eligible participants, all research
- 43 nurses for data collection, and the NEO study group: Pat van Beelen, Petra Noordijk, and Ingeborg de Jonge for
- 44 study coordination, laboratory, and data management.

46 Abstract

- 47 Per- and polyfluoroalkyl substances (PFAS) are widely used and persistent chemicals, leading to ubiquitous
- 48 exposure. Although high PFAS levels have been associated with an adverse cardiovascular risk profile, the
- 49 distribution of levels and relations with cardio-metabolic risk markers in the general population have not been
- 50 fully characterized. We assessed the association between blood levels of perfluorooctaneic acid (PFOA),
- 51 perfluorooctane sulfonic acid (PFOS), and perfluorohexanesulfonic acid (PFHxS) and a range of lipoproteins
- 52 and metabolites as well as clinical lipid measurements. We used data from participants of the Netherlands
- 53 Epidemiology of Obesity study (NEO) (n= 584) and the Rhineland Study (n= 1,962), jointly spanning an age
- range of 30 to 89 years. PFAS were measured with the Metabolon HD4 platform, and lipoprotein and metabolite
- 55 profiles were measured using Nightingale's nuclear magnetic resonance-spectroscopy platform, and mainly
- 56 comprised lipoprotein markers. Using linear regression analyses, we quantified age-, sex- and education-
- 57 adjusted associations of PFOA, PFOS, and PFHxS with clinical lipid measurements and 224 lipoproteins and
- 58 metabolites.
- 59 Higher levels of PFAS, particularly PFOS and PFHxS, were associated with higher concentrations of total lipid,
- 60 cholesterol and phospholipid content in most HDL, IDL, LDL and VLDL subclasses. The effect sizes were age-
- 61 dependent for the majority of the associations, with the deleterious effects of PFAS being generally stronger in
- 62 people below compared to those above median age. Our observation that in the general population even low
- 63 PFAS concentrations are associated with an unfavorable lipid profile, calls for further critical regulation of
- 64 PFAS substances.

65 1. Introduction

66	Per- and polyfluoroalkyl substances (PFAS) are man-made chemicals that have been widely used in many
67	industrial processes and products since the 1950s (Roth et al. 2021). These chemicals are persistent and resilient
68	in nature, allowing them to circulate in water sources and become widespread around the globe, making them
69	colloquially known as the 'forever chemicals' (RIVM ; Nordby, Luck 1956; Stockholm Convention on
70	Persistent Organic Pollutants (POPs) 2001; Buck et al. 2011; Priestly 2018; Sunderland et al. 2019; Grandjean et
71	al. 2020; Schrenk et al. 2020). High environmental PFAS levels may be caused by contamination in the vicinity
72	of PFAS-producing factories, but also by the use and breakdown of PFAS-containing products-such as fire
73	extinguishers, non-stick cooking pans, certain food packaging, textiles, clothing, cosmetics, and pesticides
74	(Sunderland et al. 2019; Barhoumi et al. 2022). Human exposure can occur through contact with a contaminated
75	environment (e.g. through dermal exposure or inhalation), contact with PFAS-containing products, as well as
76	ingestion with drinking water and food (Sunderland et al. 2019). Given the persistence of PFAS, human
77	exposure is ubiquitous and chronic. PFAS accumulate in the human body over time as they are broken down
78	slowly, where the half-life of common PFAS is estimated to be between 4 and 8.5 years (Olsen et al. 2007).
79	Ever since the introduction of PFAS production, health concerns were raised (Nordby, Luck 1956; 3M
80	Company Chemical Division 1963; Sherman 1973; Sunderland et al. 2019). The main focus has long been on
81	direct exposure to high levels of PFAS, which was found to be associated with a range of adverse health
82	outcomes, including obesity, kidney disease, cancer, thyroid disease, hypercholesteremia, dyslipidemia, liver
83	damage, reduced antibody response to vaccination, and a higher risk of severe course of COVID-19 (Stockholm
84	Convention on Persistent Organic Pollutants (POPs) 2001; Priestly 2018; Grandjean et al. 2020; Schrenk et al.
85	2020). Animal studies and studies in high-risk groups, such as children, who are at high risk of adverse effects,
86	and high exposure groups, such as factory workers, have found PFAS to be related with changes in the immune
87	system, proteome, hormones, and metabolome (Liu et al. 2022; Shih et al. 2022). However, evidence of the
88	effects of PFAS in humans remains limited and more research about the presence and the effects of low
89	exposure in the general population is warranted (Sunderland et al. 2019; European Food Safety Authority 2020).
90	The health concerns from PFAS exposure resulted in the classification of certain PFAS as persistent pollutants
91	that require regulation. Specifically, the use of perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid
92	(PFOA) has been subjected to growing restrictions (Stockholm Convention on Persistent Organic Pollutants
93	(POPs) 2001; Stockholm Convention on Persistent Organic Pollutants (POPs) 2017). However, despite the
94	increasing scrutiny, many PFAS species remain unregulated and even PFOA and PFOS are not yet fully banned
95	in the European Union (RIVM 2022a). Thus, and worsened by their long half-life, PFAS exposure remains a
96	public health issue (Duffek et al. 2020; Schrenk et al. 2020; RIVM 2021).
97	Specific mechanisms through which PFAS exert their effects remain largely unclear. Previous studies have
98	shown that PFAS are most consistently associated with changes in lipid metabolism, particularly higher
99	cholesterol levels (Priestly 2018). Recent advances in high throughput metabolomic approaches allow the
100	analysis of large lipoprotein and metabolite panels and enable more in-depth examinations of lipid species and

- 101 lipoprotein subclasses. Indeed, a recent study investigated the effect of PFAS on an extensive lipid panel in a
- sample of 50-year old adults (Haug et al. 2023). We aim to corroborate and expand upon that work by including
- a larger group and a wider age range. Especially, we aim to evaluate PFAS exposure levels in the general

- 104 population and investigate their association with metabolites and lipoproteins, using clinical lipid measurements
- and targeted metabolomics. To enhance generalizability and robustness of the results, we used two different
- study populations: the Netherlands Epidemiology of Obesity study (NEO) (n = 584) and the Rhineland Study (n

107 = 1,962).

109 2. Methods

110 2.1. Study Populations

111 2.1.1. Netherlands Epidemiology of Obesity Study

112 NEO is a population-based, prospective cohort study of individuals aged 45–65 years, with an oversampling of

113 individuals who are overweight or have obesity. Men and women aged between 45 and 65 years with a self-

- 114 reported body mass index (BMI) of 27 kg/m² or higher, living in the greater area of Leiden (in the West of the
- 115 Netherlands) were eligible to participate in the NEO study. In addition, all inhabitants aged between 45 and 65
- 116 years from one municipality (Leiderdorp) were invited, irrespective of their BMI. Recruitment of participants
- started in September 2008 and was completed at the end of September 2012. In total, 6,671 participants have
- 118 been included. Participants were invited to come to the NEO study center of the LUMC for one baseline study
- visit, where a blood sample of 108 mL was taken from the participants after an overnight fast of at least 10
- 120 hours (de Mutsert et al. 2013). In the current study, the samples of a random subset of 599 participants from the
- 121 Leiderdorp sub-population (n=1,671) were used to measure untargeted metabolomic data. Among these
- 122 individuals, 4 did not have the study outcome (targeted metabolomics) data, 2 were excluded due to missing
- data on educational level, and 9 were excluded due to measurement errors, leading to a final sample size of n =
- 124 584 (**Figure 1**).

125 2.1.2. Rhineland Study

- 126 The Rhineland Study is an ongoing community-based cohort study located in two geographically defined areas
- 127 in Bonn, Germany. Participation is possible by invitation only. To be able to participate, participants had to be
- 128 above 30 years of age at baseline and have sufficient command of the German language to provide written
- 129 informed consent. Nightingale measurements were performed in plasma from the first 2,000 consecutive
- 130 participants, 1,982 of which passed quality control. We further excluded 20 participants due to missing data on
- educational level, leaving a sample size of n=1,962 to be included in the analyses (Figure 1). Of these, 1,805
- 132 participants had complete data on LDL, HDL, total triglyceride, and cholesterol levels, which were used for the
- analysis of clinical lipid measurements.

134 2.2. PFAS measurements

135 Blood PFAS concentrations were measured using the untargeted Metabolon[™] Discovery HD4 platform at

- 136 Metabolon Inc. (Durham, North Carolina, USA). In brief, this process involves four independent ultra-high-
- 137 performance liquid chromatography mass spectrometry (UHPLC-MS/MS) platforms (Evans et al. 2014; Rhee et
- al. 2019). It uses two positive ionization reverse phase chromatography, one negative ionization reverse phase
- 139 chromatography, and one hydrophilic interaction liquid chromatography negative ionization (Rhee et al. 2019).
- 140 In NEO, PFOA and PFOS levels were quantified from fasting state serum samples, while in the Rhineland
- 141 Study PFOA, PFOS and perfluorohexanesulfonic acid (PFHxS) concentrations were obtained from fasting
- 142 plasma samples. PFAS were quantified as relative concentrations using the mass and charge peaks of the
- 143 molecules. PFHxS was not measured in NEO, because it was not detectable in serum samples after the
- 144 necessary sample preparations. To ensure comparability across studies, we Z-standardized all PFAS levels
- before subsequent analyses. The distribution of PFAS levels in the different studies can be found in
- 146 Supplementary Figure 1.

147 2.3. Metabolic and lipoprotein measurements

- 148 Clinical lipids, i.e. total serum levels of LDL, HDL and total cholesterol, and triglycerides, were measured in
- 149 NEO as described previously (de Mutsert et al. 2013). In the Rhineland Study, serum levels of LDL, HDL and
- total cholesterol, and triglycerides, were measured using routine methods at the University Hospital in Bonn.
- 151 Fasting serum (NEO) and plasma (Rhineland Study) metabolite levels were quantified using the Nightingale
- 152 nuclear magnetic resonance untargeted metabolomic platform (Nightingale Health Ltd, Helsinki, Finland),
- 153 which quantifies 224 metabolites and metabolite ratios. The platform predominantly provides detailed
- 154 lipoprotein lipid information, in addition to absolute concentrations of various other metabolites, including
- amino acids, free fatty acids and ketone bodies (Soininen et al. 2015).

156 2.4. Assessment of covariates

- 157 In both the Rhineland Study and NEO, questionnaire and food frequency questionnaires were used to collect
- demographic and lifestyle information, including current smoking status (yes/no), alcohol intake (g/day), and
- education (low/middle/high). In the Rhineland Study, missing values (n= 163) for smoking were imputed based
- 160 on HD4-measured cotinine levels in the blood according to the method described by St Helen et al. (St Helen et
- al. 2012). To assure the quality of the data, alcohol values belonging to participants reporting an overall
- improbable caloric intake (<600 or >8,000) were excluded, as per the method of Galbete et al. (Galbete et al.
- 163 2018). The name, dosage, anatomical therapeutic chemical (ATC) code and prescription status of each
- 164 medication that participants were currently taking, or had taken in the past year, were recorded in an interview.
- 165 Use of lipid-lowering mediation was based on ATC code C10 in the Rhineland Study and ATC codes C10AA or
- 166 C10BA in NEO.
- 167 The International Standard Classification of Education 2011 (ISCED) (UNESCO Institute for Statistics 2012)
- 168 was used to standardize education across both studies. Participants' education level was reclassified as low
- 169 (lower secondary education or below), middle (upper secondary education to undergraduate university level) or
- 170 high (postgraduate university study) in both studies.

171 2.5. Statistical Analysis

- 172 2.5.1. Imputation of Missing Metabolite Values
- 173 A total of 224 metabolites were measured on the targeted metabolomics Nightingale platform. These
- 174 metabolites had missing values ranging from 0.3% to 9%. Missing values were set to 0 where the levels were
- 175 considered to be below detection. Missingness due to other reasons (according to the flagging of missing status
- 176 by Nightingale, e.g. as 'equipment failure') was imputed using a previously described pipeline (Faquih et al.
- 177 2020). Accordingly, imputed datasets were generated using multiple imputation. To ensure normality, all
- 178 metabolites were log-transformed after adding 1 to account for 0s.
- 179 2.5.2. Linear Regression Models
- 180 Multiple linear regression models were used to associate the log-transformed and Z-standardized PFAS
- 181 concentrations (exposures) with the log-transformed Nightingale and clinical lipid measurements (outcomes). In
- 182 our first models, we adjusted for biological sex (women/men), age (years) and education (low/middle/high). As
- 183 PFAS accumulate during the lifespan (Pérez et al. 2013) and may have different effects across age groups, we
- 184 next included a multiplicative interaction term between age and the PFAS substances. We also assessed possible

- 185 effect differences between men and women (Koskela et al. 2022) by additionally including a sex-interaction
- term to our models. If the interaction estimate was significant, we performed a stratified analysis on the basis of
- 187 sex or the median age (54 years). For ease of comparability in the figures, analyses were run on the Z-
- 188 standardized metabolite levels after the log transformation. To test whether the associations were dependent on
- traditional risk behaviors and medication use, we ran additional analyses adjusting for alcohol intake, smoking,
- 190 BMI and lipid-lowering medication. Moreover, we assessed the robustness of our results by performing a
- 191 sensitivity analysis where we truncated extreme outlier values (>5 standard deviations (SDs)) in the PFAS
- 192 levels.
- 193 2.5.3. Multiple testing correction
- 194 As the Nightingale measurements are inherently highly correlated, we used the method described by Li and Ji
- 195 (Li, Ji 2005) to calculate the effective number of independent variables. Accordingly, the number of
- 196 independent Nightingale variables was estimated at 66. We furthermore included 4 clinical lipid measurements
- as outcomes. Thus, we considered a p-value < 0.0007 (0.05/70) as statistically significant.
- 198 All analyses were performed using R (R Core Team 2019) v4.1.0 (2021-05-18) in NEO and v4.0.5 (2021-03-31)
- in the Rhineland Study. Figures were created using the *ggplot2* (Hadley 2016) R package.

201 3. Results

202 **3.1. Population characteristics**

- 203 Participants in the Rhineland Study (57% women) had a median age of 54 years (range: 30 89), an average
- BMI of 25.8 (SD: 4.5), and a relatively high education level (Table 1). NEO participants (52.6% women) had a
- 205 median age of 54 years (range: 45 66), an average BMI of 25.9 (SD: 4.0), and were mostly of a medium
- education level. Average alcohol consumption in the Rhineland Study was higher than in the NEO study.
- 207 Current smokers made up 13.7% of the Rhineland Study and 11.3% of NEO. PFOA and PFOS were measurable
- 208 in all 599 NEO participants. In the Rhineland Study, PFOA, PFOS, and PFHxS were below the level of
- detection in none, 17, and three out of 1,962 participants, respectively.

210 3.2. PFAS and clinical lipids

- 211 In the overall analyses, no associations were found between PFOA, PFOS or PFHxS and the clinical lipid
- 212 measurements when adjusting for age, sex and education (Table 2). While this did not differ between men and
- 213 women, we found statistically significant age-interaction effects for some of the associations (Rhineland Study:
- 214 PFOS and PFHxS with total cholesterol, PFOA and PFOS with LDL-C; NEO: PFOS with total cholesterol and
- LDL-C). In the subsequent age-stratified analyses (≤54 years; >54 years) we only found an association of PFOS
- 216 with higher cholesterol levels in the younger age group in NEO (Supplementary Table 1, Supplementary
- 217 Table 2).

218 3.3. PFAS and metabolic profiles

219 Overall, all PFAS substances were usually, albeit largely non-significantly, associated with higher levels of

- 220 different cholesterols, fatty acids and the lipid content of differently-sized IDL, LDL and VLDL subclasses after
- 221 adjustment for sex, age and education. Statistically significant associations were observed between PFOA and a
- higher concentration and lipid content of small HDL particles in NEO and between PFOA and sphingomyelins,
- 223 cholesterol in HDL3, and albumin in the Rhineland Study. PFOS was statistically significantly associated with
- higher fatty acid levels in NEO, while PFHxS was statistically significantly associated with higher levels of
- 225 cholesterols, fatty acids, albumin, and apolipoprotein A1 (apoA1), and with lower levels of the amino acid
- 226 phenylalanine in the Rhineland Study (Figure 2).
- 227 We found significant age-interactions for PFOA (NEO: 5; Rhineland Study: 1) and PFHxS (Rhineland Study:
- 228 n= 8), and many for PFOS (NEO: 54; Rhineland Study: 80) in both studies. These age-effects were observed for
- almost all lipoprotein and metabolite classes, including cholesterol, cholesterol ester and total lipid content of
- 230 IDLs, LDLs, and VLDLs, as well as apolipoprotein B (apoB), fatty acids, amino acids, albumin, and
- 231 sphingomyelin levels. The associations were almost always stronger in the younger compared to the older age
- group (Figure 3).
- Lastly, we checked whether the above-mentioned associations were confounded by smoking, alcohol
- consumption, BMI, and lipid-lowering medication (Supplementary Table 1, Supplementary Table 2). In
- NEO, the associations remained largely unchanged. In the Rhineland Study, the number of significant
- associations changed across all PFAS substances. However, while additional adjustment decreased the strength

- 237 of the effect, particularly when including BMI or alcohol intake, the previously described patterns remained
- 238 largely the same.
- 239 Truncating outliers of PFAS levels did not substantially change the results in NEO, but slightly increased the
- 240 number of significant associations in the Rhineland Study (Supplementary Table 1, Supplementary Table 2),
- 241 indicating that the observed associations were not driven by outliers.

242

244 4. Discussion

245 4.1. Summary

246 In this study, we investigated the association of three PFAS substances with clinically measured lipid 247 biomarkers and a wide range of metabolites (n = 224) in the general population. By combining findings from the 248 NEO Study (n= 584) and the Rhineland Study (n= 1,962), we report common and clinically relevant effects of 249 PFAS on measures of lipid metabolism. Specifically, PFOS and PFHxS were associated with an adverse 250 metabolomic profile characterized by increased levels of apoB, phosphoglycerides, total lipids, fatty acids, and 251 the lipid content of LDL, IDL, and VLDL particles. The effect estimates were consistent with regard to both 252 direction and magnitude in both cohorts and were not driven by outliers, further supporting the validity of our 253 findings. Thus, we interpret our data to indicate that even low PFAS levels in the general population can have a

254 detrimental effect on lipid metabolism.

255 4.2. Widespread PFAS exposure in the Netherlands and Germany

256 PFAS exposure is widespread in both Germany (Brede et al. 2010; Duffek et al. 2020; German Environment 257 Agency 2020; Kotthoff et al. 2020) and the Netherlands (Gebbink, van Leeuwen 2020; RIVM 2021; van der Aa 258 2021; RIVM 2022b). Despite the slow phasing out of the production of PFAS substance in the Netherlands 259 (Municipality of Dordrecht 2022), both surface and ground water, soil, vegetation, fish, and stock animals in the 260 area remain highly contaminated. In addition, contamination in surface and drinking water was detected across 261 the western regions of the Netherlands (Gebbink, van Leeuwen 2020). Recently, the National Institute for the 262 Public Health and the Environment (RIVM) concluded that the levels of PFAS in the Netherlands are highly 263 concerning and require further research (RIVM 2021). PFAS exposure is also a problem in Germany, where 264 areas along the Rhine among others are marked as high exposure locations (Brendel et al. 2018; Kotthoff et al. 265 2020). Importantly, PFAS levels are detectable in the groundwater of most and soil samples of all states 266 (German Environment Agency 2020). Indeed, in line with the high contamination levels of both countries and 267 the long half-life of PFAS in human serum of between 4 and 8.5 years (Olsen et al. 2007; Schrenk et al. 2020), 268 we found that PFAS levels were detectable in the blood of nearly all included participants from NEO and the 269 Rhineland Study.

270 4.3. PFAS levels associated with metabolomic profiles of increased risk of cardiovascular disease

271 We found that even low PFAS levels were associated with a distinctive lipid profile, characterized by higher

- 272 cholesterol and lipid content in HDL, IDL, LDL, and VLDL subclasses. We also found associations between
- 273 PFAS levels and apoB, fatty acids, phosphoglycerides, IDL, and phospholipids, which is largely in line with a
- 274 recent, smaller study among 50-year-old individuals in Sweden (Haug et al. 2023). A higher lipid content of
- 275 lipoproteins has been implicated in cardiovascular disease (CVD) (Xiao et al. 2016), while higher levels of fatty
- acids and apoB have been consistently associated with myocardial infarction (Julkunen et al. 2022). Other
- 277 studies have linked a similar metabolomic profile to a higher risk of cardiometabolic diseases such as CVD
- 278 (Tikkanen et al. 2021), hypertension (Palmu et al. 2022), type 2 diabetes (Ahola-Olli et al. 2019), and non-
- alcoholic fatty liver disease (Sliz et al. 2018). Therefore, our results suggest that PFAS exposure may increase
- the risk of cardiometabolic outcomes by impacting the lipoprotein profile. Of note, we found that PFHxS, one of
- the often-used more recent substitutes of PFOA and PFOS (Sunderland et al. 2019; Li et al. 2020), affected
- 282 metabolite concentrations as well as lipoprotein composition and concentrations in the same way as PFOA and

PFOS. Additional adjustment for certain risk behaviors (alcohol consumption, smoking), obesity and lipidlowering medication, generally decreased the strength of and number of significant associations, but did not
substantially change the overall patterns. Thus, the risks associated with PFAS are largely independent of these
other factors.

287 4.4. Effects of PFAS are partially dependent on age

288 Our population studies jointly covered a wide age-range (30-89 years), which allowed us to investigate whether 289 the effects of PFAS levels in adults differed across age. We found significant age-interactions for most of the 290 PFOA and PFOS associations with lipoproteins, with the effects generally being larger in younger individuals. 291 On the other hand, the associations of PFHxS with metabolite outcomes were less dependent on age. It is 292 unclear what underlies the stronger effects of PFOA and PFOS in younger people. A possible explanation could 293 be the presence of more competing causes in older people, including changes in cholesterol and other lipid 294 levels later in life due to medication use, change in body composition, hormones or diet (Ettinger et al. 1992; 295 Ferrara et al. 1997; Downer et al. 2014; Zhang et al. 2020). Alternatively, it is possible that the timing and 296 duration of a person's exposure impact the effect. For example, early life exposure reportedly has more severe 297 consequences than late-life exposure (Canova et al. 2021). Finally, it may be that the intensity of exposure, 298 rather than cumulative exposure, is an important determinant of the physiological impact of PFAS exposure. 299 Due to the long half-life, the same blood exposure level may result from lower exposures over a longer time 300 period in older compared to younger persons. This might also explain why no clear age-effects were seen for 301 PFHxS: as that has been in use much shorter, blood levels may reflect more similar exposure patterns between 302 younger and older persons.

303 4.5. Strengths and limitations

304 Our main limitation stems from the cross-sectional nature of our data. As such, we cannot establish a causal link 305 between the PFAS exposures and the metabolites. Nonetheless, reverse causation is unlikely due to the nature of 306 the associations, as it is highly unlikely that lipoprotein concentrations would affect PFAS levels. Other 307 limitations include the use of different sample media for the measurement of PFAS and Nightingale metabolites 308 in NEO versus the Rhineland Study, as well as the use of relative, rather than absolute, PFAS levels. A strength 309 of our study is that we comprehensively evaluated the effect of PFAS exposure in relation to a detailed lipid

- 310 profile and a large variety of metabolites across a wide age-range, which has not been assessed before.
- 311 Moreover, we found consistent and robust associations of PFAS levels with a cardio-metabolic risk profile
- 312 across two independent European studies, which supports the reliability of our findings. Moreover, our results
- are in line with findings from a smaller, recent study (Haug et al. 2023), which further corroborates the validity
- of our results.

315 4.6. Conclusion

- 316 In conclusion, we found that even low levels of PFAS are associated with a detrimental lipid profile in the
- 317 general population. We report associations between PFAS and higher apoB and lipid content, particularly
- 318 cholesterol content, of most subclasses of IDL, LDL, and VLDL. Our results corroborate and expand on
- 319 previous findings by showing a clear link between PFAS levels and an adverse lipid profile across different
- 320 study populations, even at low PFAS levels. In the Netherlands, pre-determined cut-offs for safe levels of PFAS

- 321 were recently used to conclude that the PFAS levels in the Westerschelde were no cause for concern (RIVM
- 322 2022b). However, our results indicate that there may be no safe levels below which exposure is without health
- 323 hazard. Moreover, we found that a more recently developed PFAS, PFHxS, was as detrimental for health as
- 324 were older PFAS (PFOA and PFOS). Thus, stricter regulations may be required for all PFAS substances.
- 325 Furthermore, due to the persistent nature of PFAS and their recirculation in the environment, there is a need to
- 326 actively remove these chemicals from the environment—methods for which are under development (Trang et al.
- 327 2022). The combination of the well-documented persistence of PFAS and their harmful effects ensures that
- 328 exposure to these substances is an enduring public health concern, unless and until we find ways to effectively
- 329 eliminate PFAS from our environment.

331 References

- 332 3M Company Chemical Division (1963). 3m brand fluorochemical surfactants. 46.
- Ahola-Olli A. V., Mustelin L., Kalimeri M., Kettunen J., Jokelainen J., Auvinen J., Puukka K.,
- 334 Havulinna A. S., Lehtimäki T., Kähönen M. J. D. (2019). Circulating metabolites and the risk of type
- 2 diabetes: A prospective study of 11,896 young adults from four finnish cohorts. 62 (12): 2298-
- 336 2309.
- 337 Barhoumi B., Sander S. G., Tolosa I. (2022). A review on per- and polyfluorinated alkyl substances
- 338 (pfass) in microplastic and food-contact materials. Environmental Research. 206: 112595.
- 339 Brede E., Wilhelm M., Göen T., Müller J., Rauchfuss K., Kraft M., Hölzer J. (2010). Two-year
- follow-up biomonitoring pilot study of residents' and controls' pfc plasma levels after pfoa reduction
- 341 in public water system in arnsberg, germany. International Journal of Hygiene and Environmental
- 342 Health. 213 (3): 217-223.
- 343 Brendel S., Fetter É., Staude C., Vierke L., Biegel-Engler A. (2018). Short-chain perfluoroalkyl acids:
- Environmental concerns and a regulatory strategy under reach. Environmental Sciences Europe. 30
- 345 (1): 9.
- 346 Buck R. C., Franklin J., Berger U., Conder J. M., Cousins I. T., de Voogt P., Jensen A. A., Kannan K.,
- 347 Mabury S. A., van Leeuwen S. P. (2011). Perfluoroalkyl and polyfluoroalkyl substances in the
- environment: Terminology, classification, and origins. 7 (4): 513-541.
- 349 Canova C., Di Nisio A., Barbieri G., Russo F., Fletcher T., Batzella E., Dalla Zuanna T., Pitter G.
- 350 (2021). Pfas concentrations and cardiometabolic traits in highly exposed children and adolescents. Int
- 351 J Environ Res Public Health. 18 (24)
- de Mutsert R., den Heijer M., Rabelink T. J., Smit J. W., Romijn J. A., Jukema J. W., de Roos A.,
- 353 Cobbaert C. M., Kloppenburg M., le Cessie S., Middeldorp S., Rosendaal F. R. (2013). The
- netherlands epidemiology of obesity (neo) study: Study design and data collection. Eur J Epidemiol.
- 355 28 (6): 513-523.
- 356 Downer B., Estus S., Katsumata Y., Fardo D. W. (2014). Longitudinal trajectories of cholesterol from
- 357 midlife through late life according to apolipoprotein e allele status. Int J Environ Res Public Health.
- 358 11 (10): 10663-10693.
- 359 Duffek A., Conrad A., Kolossa-Gehring M., Lange R., Rucic E., Schulte C., Wellmitz J. (2020). Per-
- and polyfluoroalkyl substances in blood plasma results of the german environmental survey for
- 361 children and adolescents 2014–2017 (geres v). International Journal of Hygiene and Environmental
- 362 Health. 228: 113549.
- 363 Ettinger W. H., Wahl P. W., Kuller L. H., Bush T. L., Tracy R. P., Manolio T. A., Borhani N. O.,
- 364 Wong N. D., O'Leary D. H. (1992). Lipoprotein lipids in older people. Results from the
- 365 cardiovascular health study. The chs collaborative research group. Circulation. 86 (3): 858-869.

- 366 European Food Safety Authority (2020). Outcome of a public consultation on the draft risk
- 367 assessment of perfluoroalkyl substances in food. 17 (9): 1931E.
- 368 Evans A., Bridgewater B., Liu Q., Mitchell M., Robinson R., Dai H., Stewart S., DeHaven C., Miller
- 369 L. J. M. (2014). High resolution mass spectrometry improves data quantity and quality as compared to
- unit mass resolution mass spectrometry in high-throughput profiling metabolomics. 4 (2): 1.
- 371 Faquih T., van Smeden M., Luo J., le Cessie S., Kastenmüller G., Krumsiek J., Noordam R., van
- Heemst D., Rosendaal F. R., van Hylckama Vlieg A., Willems van Dijk K., Mook-Kanamori D. O.
- 373 (2020). A workflow for missing values imputation of untargeted metabolomics data. Metabolites. 10
- 374 (12)
- Ferrara A., Barrett-Connor E., Shan J. (1997). Total, ldl, and hdl cholesterol decrease with age in
- older men and women. The rancho bernardo study 1984-1994. Circulation. 96 (1): 37-43.
- 377 Galbete C., Kröger J., Jannasch F., Iqbal K., Schwingshackl L., Schwedhelm C., Weikert C., Boeing
- 378 H., Schulze M. B. (2018). Nordic diet, mediterranean diet, and the risk of chronic diseases: The epic-
- 379 potsdam study. BMC Medicine. 16 (1): 99.
- 380 Gebbink W. A., van Leeuwen S. P. J. (2020). Environmental contamination and human exposure to
- 381 pfass near a fluorochemical production plant: Review of historic and current pfoa and genx
- contamination in the netherlands. Environment International. 137: 105583.
- 383 German Environment Agency (2020). Pfas. Came to stay. German Environment Agency. 1-2020: 48.
- 384 Grandjean P., Timmermann C. A. G., Kruse M., Nielsen F., Vinholt P. J., Boding L., Heilmann C.,
- 385 Mølbak K. (2020). Severity of covid-19 at elevated exposure to perfluorinated alkylates. PLOS ONE.

386 15 (12): e0244815.

- Hadley W. (2016). Ggplot2: Elegant graphics for data analysis.
- Haug M., Dunder L., Lind P. M., Lind L., Salihovic S. (2023). Associations of perfluoroalkyl
- substances (pfas) with lipid and lipoprotein profiles. Journal of Exposure Science & EnvironmentalEpidemiology.
- 391 Julkunen H., Cichońska A., Tiainen M., Koskela H., Nybo K., Mäkelä V., Nokso-Koivisto J.,
- 392 Kristiansson K., Perola M., Salomaa V., Jousilahti P., Lundqvist A., Kangas A. J., Soininen P., Barrett
- 393 J. C., Würtz P. (2022). Atlas of plasma nuclear magnetic resonance biomarkers for health and disease
- in 118,461 individuals from the uk biobank. 2022.2006.2013.22276332.
- 395 Koskela A., Ducatman A., Schousboe J. T., Nahhas R. W., Khalil N. (2022). Perfluoroalkyl
- substances and abdominal aortic calcification. J Occup Environ Med. 64 (4): 287-294.
- 397 Kotthoff M., Fliedner A., Rüdel H., Göckener B., Bücking M., Biegel-Engler A., Koschorreck J.
- 398 (2020). Per- and polyfluoroalkyl substances in the german environment levels and patterns in
- different matrices. Science of The Total Environment. 740: 140116.
- 400 Li J., Ji L. (2005). Adjusting multiple testing in multilocus analyses using the eigenvalues of a
- 401 correlation matrix. Heredity (Edinb). 95 (3): 221-227.

- 402 Li J., He J., Niu Z., Zhang Y. (2020). Legacy per- and polyfluoroalkyl substances (pfass) and
- 403 alternatives (short-chain analogues, f-53b, genx and fc-98) in residential soils of china: Present
- 404 implications of replacing legacy pfass. Environment International. 135: 105419.
- 405 Liu H., Sun W., Zhou Y., Griffin N., Faulkner S., Wang L. (2022). Itraq-based quantitative
- 406 proteomics analysis of sprague-dawley rats liver reveals perfluorooctanoic acid-induced lipid
- 407 metabolism and urea cycle dysfunction. Toxicol Lett. 357: 20-32.
- 408 Municipality of Dordrecht. (2022) Dossier chemours en dupont (pfoa/c8, genx): Gezondheid.
- 409 <u>https://cms.dordrecht.nl/Inwoners/Overzicht_Inwoners/Dossier_Chemours_en_DuPont/Gezondheid.</u>
- 410 26/05/2022
- 411 Nordby G. L., Luck J. M. (1956). Perfluorooctanoic acid interactions with human serum albumin. J
- 412 Biol Chem. 219 (1): 399-404.
- 413 Olsen G. W., Burris J. M., Ehresman D. J., Froehlich J. W., Seacat A. M., Butenhoff J. L., Zobel L. R.
- 414 (2007). Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and
- 415 perfluorooctanoate in retired fluorochemical production workers. Environ Health Perspect. 115 (9):
- 416 1298-1305.
- 417 Palmu J., Tikkanen E., Havulinna A. S., Vartiainen E., Lundqvist A., Ruuskanen M. O., Perola M.,
- 418 Ala-Korpela M., Jousilahti P., Würtz P., Salomaa V., Lahti L., Niiranen T. (2022). Comprehensive
- 419 biomarker profiling of hypertension in $36\square 985$ finnish individuals. 40 (3): 579-587.
- 420 Pérez F., Nadal M., Navarro-Ortega A., Fàbrega F., Domingo J. L., Barceló D., Farré M. (2013).
- 421 Accumulation of perfluoroalkyl substances in human tissues. Environment International. 59: 354-
- 422 362.
- 423 Priestly B. (2018). Literature review and report on the potential health effects of perfluoroalkyl
- 424 compounds, mainly perfluorooctane sulfonate (pfos). Monash University. 44.
- 425 R Core Team (2019). R: A language and environment for statistical computing. Vienna, Austria. URL
- 426 <u>https://www.R-project.org/</u>. R Foundation for Statistical Computing.
- 427 Rhee E. P., Waikar S. S., Rebholz C. M., Zheng Z., Perichon R., Clish C. B., Evans A. M., Avila J.,
- 428 Denburg M. R., Anderson A. H., Vasan R. S., Feldman H. I., Kimmel P. L., Coresh J. (2019).
- 429 Variability of two metabolomic platforms in ckd. Clinical Journal of the American Society of
- 430 Nephrology. 14 (1): 40.
- 431 RIVM. Pfas. https://www.rivm.nl/pfas. 15-9-2021
- 432 RIVM. (2021) Te veel blootstelling aan pfas in nederland. https://www.rivm.nl/nieuws/te-veel-
- 433 <u>blootstelling-aan-pfas-in-nederland</u>. 15-9-2021
- 434 RIVM (2022a). Official start to ban pfas in europe | rivm.
- 435 RIVM (2022b). Pfas in de westerschelde: Eet zo min mogelijk zelf gevangen producten | rivm.
- 436 Roth K., Yang Z., Agarwal M., Liu W., Peng Z., Long Z., Birbeck J., Westrick J., Liu W., Petriello
- 437 M. C. (2021). Exposure to a mixture of legacy, alternative, and replacement per- and polyfluoroalkyl

- 438 substances (pfas) results in sex-dependent modulation of cholesterol metabolism and liver injury.
- 439 Environment International. 157: 106843.
- 440 Schrenk D., Bignami M., Bodin L., Chipman J. K., Del Mazo J., Grasl Kraupp B., Hogstrand C.,
- 441 Hoogenboom L., Leblanc J. C., Nebbia C. S., Nielsen E., Ntzani E., Petersen A., Sand S., Vleminckx
- 442 C., Wallace H., Barregård L., Ceccatelli S., Cravedi J. P., Halldorsson T. I., Haug L. S., Johansson N.,
- 443 Knutsen H. K., Rose M., Roudot A. C., Van Loveren H., Vollmer G., Mackay K., Riolo F.,
- 444 Schwerdtle T. (2020). Risk to human health related to the presence of perfluoroalkyl substances in
- 445 food. EFSA Journal. 18 (9)
- 446 Sharma M., Loh K. P., Nightingale G., Mohile S. G., Holmes H. M. (2016). Polypharmacy and
- 447 potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol. 7 (5): 346-353.
- 448 Sherman H. (1973). Nintey-nine feeding study in rats and dogs with zonyl rp Haskell Laboratory for
- 449 Toxicology and Industrial Medicine, DUPONT.
- 450 Shih Y. H., Blomberg A. J., Jørgensen L. H., Weihe P., Grandjean P. (2022). Early-life exposure to
- 451 perfluoroalkyl substances in relation to serum adipokines in a longitudinal birth cohort. Environ Res.
- 452 204 (Pt A): 111905.
- 453 Sliz E., Sebert S., Würtz P., Kangas A. J., Soininen P., Lehtimäki T., Kähönen M., Viikari J.,
- 454 Männikkö M., Ala-Korpela M., Raitakari O. T., Kettunen J. (2018). Nafld risk alleles in pnpla3,
- tm6sf2, gckr and lyplal1 show divergent metabolic effects. Human Molecular Genetics. 27 (12):
- 456 2214-2223.
- 457 Soininen P., Kangas A. J., Wurtz P., Suna T., Ala-Korpela M. (2015). Quantitative serum nuclear
- 458 magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc
- 459 Genet. 8 (1): 192-206.
- 460 St Helen G., Novalen M., Heitjan D. F., Dempsey D., Jacob P., 3rd, Aziziyeh A., Wing V. C., George
- 461 T. P., Tyndale R. F., Benowitz N. L. (2012). Reproducibility of the nicotine metabolite ratio in
- 462 cigarette smokers. Cancer Epidemiol Biomarkers Prev. 21 (7): 1105-1114.
- Stockholm Convention on Persistent Organic Pollutants (POPs). (2001) The new pops under thestockholm convention.
- 465 http://www.pops.int/TheConvention/ThePOPs/TheNewPOPs/tabid/2511/Default.aspx.
- 466 Stockholm Convention on Persistent Organic Pollutants (POPs) (2017). The 16 new pops: An
- 467 introduction to the chemicals added to the stockholm convention as persistent organic pollutants by
- the conference of the parties.
- 469 Sunderland E. M., Hu X. C., Dassuncao C., Tokranov A. K., Wagner C. C., Allen J. G. (2019). A
- 470 review of the pathways of human exposure to poly- and perfluoroalkyl substances (pfass) and present
- understanding of health effects. Journal of Exposure Science & amp; Environmental Epidemiology.
 29 (2): 131-147.
- 473 Tikkanen E., Jägerroos V., Holmes M. V., Sattar N., Ala Korpela M., Jousilahti P., Lundqvist A.,
- 474 Perola M., Salomaa V., Würtz P. (2021). Metabolic biomarker discovery for risk of peripheral artery

- disease compared with coronary artery disease: Lipoprotein and metabolite profiling of 31 657
- 476 individuals from 5 prospective cohorts. Journal of the American Heart Association. 10 (23): e021995.
- 477 Trang B., Li Y., Xue X.-S., Ateia M., Houk K. N., Dichtel W. R. (2022). Low-temperature
- 478 mineralization of perfluorocarboxylic acids. 377 (6608): 839-845.
- 479 UNESCO Institute for Statistics (2012). International standard classification of education isced 2011.
- 480 Montreal, Quebec H3C 3J7 Canada, UNESCO Institute for Statistics 88.
- 481 van der Aa M. H., Julia; te Biesebeek, Jan Dirk (2021). Analyse bijdrage drinkwater en voedsel aan
- 482 blootstelling efsaeuropese voedselveiligheidsautoriteit-4 pfaspoly- en perfluoralkylstoffen in
- 483 nederland en advies drinkwaterrichtwaarde. Rijksinstituut voor Volksgezondheid en Milieu.
- 484 Ministerie van Volksgezondheid, Welzijn en Sport.
- 485 Xiao C., Dash S., Morgantini C., Hegele R. A., Lewis G. F. (2016). Pharmacological targeting of the
- 486 atherogenic dyslipidemia complex: The next frontier in cvd prevention beyond lowering ldl
- 487 cholesterol. Diabetes. 65 (7): 1767-1778.
- 488 Zeilmaker M. J. J., P. ; Versteegh, A. ; Pul, A. van ; Vries, W. de ; Bokkers, B. ; Wuijts, S. ; Oomen,
- 489 A. ; Herremans, J. (2016). Risicoschatting emissie pfoa voor omwonenden. Bilthoven: National
- 490 Institute for Public Health and the Environment.
- 491 Zhang P., Su Q., Ye X., Guan P., Chen C., Hang Y., Dong J., Xu Z., Hu W. (2020). Trends in ldl-c
- and non-hdl-c levels with age. Aging Dis. 11 (5): 1046-1057.

494 Statements and Declarations

495 Funding

- 496 The NEO study is supported by the participating Departments, Division, and Board of Directors of the Leiden
- 497 University Medical Center, and by the Leiden University, Research Profile Area Vascular and Regenerative
- 498 Medicine. D.O. Mook-Kanamori. is supported by Dutch Science Organization (ZonMW-VENI Grant No.
- 499 916.14.023). D. van Heemst. and R. Noordam were supported by a grant of the VELUX Stiftung [grant
- number 1156]. T.O. Faquih was supported by the King Abdullah Scholarship Program and King Faisal
- 501 Specialist Hospital & Research Center [No. 1012879283]. The Rhineland Study was partly supported by the
- 502 German Research Foundation (DFG) under Germany's Excellence Strategy (EXC2151-390873048) and
- 503 SFB1454 project number 432325352; the Federal Ministry of Education and Research under the Diet-Body-
- 504 Brain Competence Cluster in Nutrition Research (grant numbers 01EA1410C and FKZ:01EA1809C) and in the
- framework "PreBeDem Mit Prävention und Behandlung gegen Demenz" (FKZ: 01KX2230); and the
- 506 Helmholtz Association under the Initiative and Networking Fund (No. RA-285/19) and the 2023 Innovation
- 507 Pool.

508 Competing Interests

- 509 **R. Li-Gao** is a part-time clinical research consultant for Metabolon, Inc. All other authors have no relevant
- 510 financial or non-financial interests to declare.

511 Author Contributions

- 512 T.O. Faquih: Conceptualization, Methodology, Formal Analysis, Writing Original Draft Preparation,
- 513 Visualization; E.N. Landstra.: Conceptualization, Methodology, Formal Analysis, Writing Original Draft
- 514 Preparation, Visualization; A. van Hylckama-Vlieg: Conceptualization, Supervision, Writing Reviewing and
- 515 Editing; N. A. Aziz: Conceptualization, Methodology, Writing Review and Editing; R. Li-Gao: Writing –
- 516 Review and Editing; R. de Mutsert: Project Administration, Resources, Funding Acquisition, Writing Review
- 517 and Editing; F.R. Rosendaal.: Study design, Funding acquisition, Conceptualization; R. Noordam and D. van
- 518 Heemst: Funding acquisition, Writing Review and Editing; D.O. Mook-Kanamori: Conceptualization,
- 519 Methodology, Resources, Writing Reviewing and Editing, Funding Acquisition, Supervision; K.W. van Dijk:
- 520 Conceptualization, Supervision, Writing Reviewing and Editing; M.M.B. Breteler: Conceptualization,
- 521 Methodology, Resources, Writing Reviewing and Editing, Data Curation, Funding Acquisition, Supervision.
- 522
- 523 All authors read and approved the final manuscript
- 524

525 Data availability

- 526 Due to the privacy of the participants of the NEO study and legal reasons, we cannot publicly deposit the data.
- 527 Furthermore, NEO study participants did not sign informed consent to make their data publicly available. Data
- 528 can be made available upon request to interested qualified researchers. Data requests should be sent to the NEO
- 529 Executive Board which can be contacted via <u>https://www.lumc.nl/org/neo-studie/contact/</u>.
- 530 Rhineland Study data used for this manuscript are not publicly available due to data protection regulations.
- 531 Access to data can be provided to scientists in accordance with the Rhineland Study's Data Use and Access
- 532 Policy. Requests for additional information and/or access to the datasets can be send to <u>RS-DUAC@dzne.de</u>.

- 533 All authors had full access to their respective study data and take responsibility for the integrity of the data and
- the accuracy of the analysis.
- 535

536 Ethics approval

- 537 The NEO study was approved by the medical ethical committee of the Leiden University Medical Centre
- 538 (LUMC) and all participants gave their written informed consent.
- 539
- 540 The ethics committee of the medical faculty of the University of Bonn approved the undertaking of the
- 541 Rhineland Study and it was carried out according to the recommendations of the International Council for
- 542 Harmonisation Good Clinical Practice standards.
- 543

544 Consent to participate

- 545 Written informed consent was acquired from all participants per the Declaration of Helsinki in both the NEO
- 546 and Rhineland Study.

Tables and Figures





Characteristic [†]		NEO		Rhineland Study			
Characteristic	All $(n = 584)$	<i>Women</i> (<i>n</i> = 308)	<i>Men (n= 276)</i>	All $(n = 1,962)$	Women (n= 1,104)	<i>Men</i> (<i>n</i> = 858)	
Age (median years (range))	56 (45 - 66)	56 (45 - 66)	56 (45 - 66)	54 (30 - 95)	54 (30 - 95)	54 (30 - 93)	
Sex (Women (%))	308 (52.7)			1104 (56.3)			
PFOA (mean (SD))	1.07 (0.50)	1.06 (0.51)	1.08 (0.49)	1.11 (0.53)	1.10 (0.62)	1.13 (0.46)	
PFOS (mean (SD))	1.08 (0.56)	1.09 (0.60)	10.6 (0.53)	1.21 (0.8)	1.05 (0.91)	1.41 (1.71)	
PFHxS (mean (SD))				1.09 (0.69)	0.99 (0.61)	1.22 (0.77)	
Education (N (%))							
Low	97.0 (16.6)	40 (14.5)	57 (18.5)	46 (2.3)	38 (3.4)	8 (0.9)	
Middle	391 (67.0)	173 (62.7)	218 (70.8)	871 (44.4)	542 (49.1)	329 (38.3)	
High	h 96 (16.4) 63 (22.7)		33 (10.7)	1045 (53.3) 524 (47.5)		521 (60.7)	
BMI (kg/m ² (SD))	25.9 (4.0)	26.6 (3.5)	25.3 (4.4)	25.8 (4.5)	25.3 (4.7)	26.3 (4.2)	
LDL (mmol/L (SD))	3.6 (0.9)	3.6 (0.9)	3.6 (1.0)	3.2 (0.9)	3.2 (0.9)	3.3 (0.,9)	
HDL (mmol/L (SD))	1.6 (0.5)	1.3 (0.3)	1.8 (0.4)	1.7 (0.5)	1.9 (0.5)	1.4 (0.4)	
Cholesterol (mmol/L (SD))	5.7 (1.1)	5.6 (1.0)	5.9 (1.1)	5.2 (1.0)	5.3 (1.0)	5.1 (1.0)	
Triglycerides (mmol/L (SD))	1.2 (0.8)	1.4 (0.9)	1.0 (0.6)	1.3 (0.8)	1.1 (0.6)	1.5 (1.0)	
Smoking (N (%))	66 (11.3)	31 (11.2)	35 (11.4)	269 (13.7)	134 (12.1)	135 (15.7)	
Alcohol (g/day (SD)) [‡]	14.0 (15.3)	19.0 (18.8)	9.6 (10.1)	19.4 (25.8)	15.4 (20.4)	24.7 (30.7)	

557 Table 1: Population characteristics of NEO and the Rhineland Study

Notes

[†] Number of missing values in the Rhineland Study: BMI (n= 13; 0.7%), LDL (n= 157; 8.0%), HDL (n= 157; 8.0%), Cholesterol (n= 157; 8.0%), Triglycerides (n= 157; 8.0%), Smoking (n= 0; 0%), Alcohol (n= 234; 11.9%)

[‡] In the Rhineland Study, alcohol intake of participants reporting an overall improbable caloric intake (<600 or >8,000) were excluded.

Abbreviations: Standard deviation (SD), perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorohexanesulfonic acid (PFHxS), body mass index (BMI), low density lipoprotein (LDL), high density lipoprotein (HDL)

PFAS	Study		LDL-C	LDL-C		HDL-C		Total cholesterol		Triglycerides	
		Model [†]	β [95%CI]	p -value ^{\perp}	β [95%CI]	p-value [⊥]	β [95%CI]	p -value ^{\perp}	β [95%CI]	p -value ^{\perp}	
PFOA	NEO	Overall	0.019 [0.001; 0.036]	0.0413	0.016 [0.004; 0.029]	0.0112	0.020 [0.007; 0.034]	0.0025	0.013 [-0.010; 0.036]	0.2787	
	Rhineland Study	Overall	0.005 [-0.006; 0.016]	0.388	0.007 [-0.001; 0.016]	0.0690	0.008 [-0.001; 0.016]	0.0665	-0.001 [-0.015; 0.014]	0.9362	
PEOS	NEO	Overall	0.023 [0.004; 0.041]	0,0153	0.007 [-0.006; 0.021]	0.2675	0.020 [0.007; 0.034]	0.0037	0.016 [-0.009; 0.040]	0.2031	
1105	Rhineland Study	Overall	0.007 [-0.003; 0.017]	0.1726	0.005 [-0.002; 0.013]	0.1575	0.007 [-0.001; 0.014]	0.0837	-0.005 [-0.018; 0.008]	0.4502	
PFHxS	Rhineland Study	Overall	0.013 [0.003; 0.023]	0.0128	0.012 [0.004; 0.019]	0.0024	0.012 [0.004; 0.020]	0.0023	-0.006 [-0.019; 0.007]	0.3969	

559 Table 2: Relation of blood PFAS levels with clinical lipid measurements (log-transformed) in NEO and the Rhineland Study

Notes

 $^{\perp}A$ p value of < 0.0007 was considered significant after accounting for multiple testing using the Li and Ji method

[†] Models were sex-, age- and education-adjusted.

Abbreviations: Beta estimate (β), confidence interval (CI), perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), perfluorohexanesulfonic acid (PFHxS), low density lipoprotein (LDL), high density lipoprotein (HDL)



562 PFOA (A), PFOS (B), and PFHxS (C), where the top 5 significant hits are annotated



Metabolite group

576 PFHXS



Metabolite group

- 577 *Figure 3:* Beta/beta plots showing the beta estimates in the young (≤54 years) versus old (>54 years) group
- 578 where the age interaction term was significant for NEO (A, B) and the Rhineland Study (C, D, E)



588 Supplementary Figures

589 Supplementary Figure 1: Distribution of the PFAS levels in NEO (A) and the Rhineland Study (B), where

590 outliers (>5 standard deviations) are truncated for PFOA (n= 9), PFOS levels (n= 5) and PFHxS (n= 4) in the















